3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
37
Neoplasm Metastasis
6
Neoplasms
3
Ovarian Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Neoplasms by Site
1
Medulloblastoma
1
Lung Neoplasms
1
Locoregional Recurrence
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Head and Neck Neoplasms
1
HR+/HER2- Breast Cancer
1
HER2 Negative Breast Cancer
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
ER+ HER2- Advanced Breast Cancer
1
Digestive System Neoplasms
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
26
Cisplatin
17
Radiotherapy
13
Carboplatin
13
Blood Specimen Collection
10
Cetuximab
9
Docetaxel
8
Paclitaxel
7
Fluorouracil
7
Drug Therapy
7
toripalimab
5
tislelizumab
4
nimotuzumab
4
atezolizumab
4
Surveys and Questionnaires
4
Radiation
4
Chemoradiotherapy
4
Surgical Procedures, Operative
3
Radiotherapy, Intensity-Modulated
3
Biopsy
3
130-nm albumin-bound paclitaxel
3
fludarabine
2
cemiplimab
2
avelumab
2
X-Rays
2
Tocopherols
2
Tiragolumab
2
Therapeutics
2
Tablets
2
Standard of Care
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Head and Neck Neoplasms
×
ribociclib
×
Clear all
NCT05768139
2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled